临床心得:肾脏肿瘤都是肾癌吗

2018-01-16 黄吉炜 袁易初 健康报医生频道

是不是长在肾脏里的肿瘤都是肾癌呢?答案是否定的,根据肿瘤的组织学来源,一部分“长在肾脏里”的肿瘤实际上是位于肾盂的尿路上皮癌,因其与输尿管癌在组织学来源和处理方法上较为一致,因此统称为上尿路肿瘤,与肾细胞癌有较大不同。


是不是长在肾脏里的肿瘤都是肾癌呢?答案是否定的,根据肿瘤的组织学来源,一部分“长在肾脏里”的肿瘤实际上是位于肾盂的尿路上皮癌,因其与输尿管癌在组织学来源和处理方法上较为一致,因此统称为上尿路肿瘤,与肾细胞癌有较大不同。

肾盂癌和输尿管癌是一类恶性程度较高的肿瘤,发病率约占肾肿瘤的10%,占尿路上皮肿瘤的5%~10%。与膀胱癌类似,肾盂癌和输尿管癌的发生与职业性芳香胺类物质(如联苯胺和β-萘胺)接触史密切相关,另一个重要原因则是马兜铃酸类物质接触史。其病理类型多为尿路上皮癌,少数为鳞状细胞癌及腺癌。后者常因肾盂或输尿管黏膜长期受到慢性刺激(如结石或炎症),诱发恶变而形成。由于尿路上皮癌具有多中心和易种植的特点,故30%~50%肾盂癌和输尿管癌患者可伴发膀胱尿路上皮癌。

肾盂癌和输尿管癌最常见的症状为血尿,可发生于70%~80%的患者身上,既可表现为全程无痛性肉眼血尿,也可表现为镜下血尿。尿路造影常可显示肾盂或输尿管内充盈缺损,形态不规则。CTU检查有助于鉴别肾癌与肾盂癌。部分患者尿脱落细胞学检查可找到癌细胞。对于诊断不确定的患者,有条件时可行输尿管镜检查及标本刷活检。

肾盂癌及输尿管癌的治疗以外科手术为主,必要时辅以化疗。传统观念认为,上尿路上皮癌患者应行根治性切除术,即患肾连同全长输尿管及输尿管开口部位在内的膀胱袖状切除。这类患者如行局部切除,高度恶性者近100%复发,低度恶性者50%左右复发。

但随着上尿路腔内技术(如输尿管软镜及经皮肾镜)的成熟,低度恶性的上尿路上皮癌的腔内治疗(如输尿管镜下激光治疗)及随访已成为可行手段,尤其对于孤立肾患者(包括功能性孤立肾),提供了一种保存肾单位的手术方案。(文/上海交通大学医学院附属仁济医院  黄吉炜  袁易初) 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=280160, encodeId=a1a3280160e1, content=学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Fri Jan 19 21:56:37 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280159, encodeId=8d20280159dd, content=谢谢!分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Fri Jan 19 21:56:27 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490463, encodeId=c71a14904638f, content=<a href='/topic/show?id=39e32280302' target=_blank style='color:#2F92EE;'>#临床心得#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22803, encryptionId=39e32280302, topicName=临床心得)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78368759045, createdName=yaanren, createdTime=Thu Jan 18 11:59:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-19 微笑人参

    学习学习学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=280160, encodeId=a1a3280160e1, content=学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Fri Jan 19 21:56:37 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280159, encodeId=8d20280159dd, content=谢谢!分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Fri Jan 19 21:56:27 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490463, encodeId=c71a14904638f, content=<a href='/topic/show?id=39e32280302' target=_blank style='color:#2F92EE;'>#临床心得#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22803, encryptionId=39e32280302, topicName=临床心得)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78368759045, createdName=yaanren, createdTime=Thu Jan 18 11:59:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]
    2018-01-19 微笑人参

    谢谢!分享.谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=280160, encodeId=a1a3280160e1, content=学习学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Fri Jan 19 21:56:37 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=280159, encodeId=8d20280159dd, content=谢谢!分享.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220317/1c3b2db4747d42e88e5018b394979434/be0fcebf07344e9ab886c37c502e2f29.jpg, createdBy=6bb22051299, createdName=微笑人参, createdTime=Fri Jan 19 21:56:27 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490463, encodeId=c71a14904638f, content=<a href='/topic/show?id=39e32280302' target=_blank style='color:#2F92EE;'>#临床心得#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22803, encryptionId=39e32280302, topicName=临床心得)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78368759045, createdName=yaanren, createdTime=Thu Jan 18 11:59:00 CST 2018, time=2018-01-18, status=1, ipAttribution=)]